KUALA LUMPUR, June 1 (Bernama) -- The International WELL Building Institute (IWBI) has unveiled the WELL v2 pilot, a rating system to focus exclusively on the impacts of buildings on human health and wellness.
IWBI chief product officer, Rachel Gutter, in a statement said WELL v2, the next version of its pioneering WELL Building Standard, is their effort to consolidate the latest knowledge, leading research, new technology and advanced building practice to extend the benefits of WELL buildings to more people in more places.
The rating system enables project teams to pursue the interventions that matter most to their project and their community without sacrificing WELL’s comprehensive and evidence-based approach and commitment to performance verification, a statement said.
Asia has been a market leader for WELL global adoption under WELL v1. Today, there are 236 projects registered to pursue WELL, 18 of which have been WELL-certified. Total registered space in Asia is 58 million square feet with China being a top-performing country.
The refinements and enhancements to the rating system include a new feature set with fewer preconditions and weighted optimisations; a consolidation of multiple pilots into one WELL; new pathways to achieve intents, with a laser focus on feasibility for existing buildings and commercial interiors, and a new approach to performance verification, allowing projects to contract local providers.
IWBI chief executive officer and chairman, Rick Fedrizzi said: "WELL v2 is simpler, clearer, focused on the aspects that have the greatest impact, and designed for improved return across every metric." WELL v2 is informed by key lessons learned from the nearly 1,000 projects that are registered or certified in 33 countries across the world. Users can register for WELL v2 starting today.
More information on the rating system at https://v2.wellcertified.com.
By Nadia Jumri
KUALA LUMPUR (Bernama) – The world has been battling COVID-19 for close to a year now, with more than 200 countries and territories affected by the pandemic.
In Malaysia, the third wave of infections led to total case numbers spiking to over 75,000. Globally, the virus has infected more than 68 million people and caused over 1.5 million fatalities.
Due to the virus’ highly virulent nature, producing COVID-19 test kits has become a top priority for certain biotechnology companies focusing on research and development (R&D) in Malaysia.read more ››
Pandangan rakyat Malaysia tentang peningkatan sasaran pemberian vaksin COVID-19 kepada 70 peratus.